Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin, Genzyme), Tacrolimus (Prograf, Astellas), Mycophenolate Mofetil (CellCept, Roche) and Corticosteroid Minimization.

Trial Profile

Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin, Genzyme), Tacrolimus (Prograf, Astellas), Mycophenolate Mofetil (CellCept, Roche) and Corticosteroid Minimization.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Bortezomib (Primary) ; Corticosteroids; Mycophenolate mofetil; Rituximab; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Planned end date changed from 1 Dec 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top